Study: JAK Inhibitors May Have Different Side Effects.

DRUG side effects; TUMOR risk factors; STROKE risk factors; THROMBOSIS risk factors; CARDIOVASCULAR diseases risk factors; JANUS kinases; RISK assessment; UNITED States. Food & Drug Administration; RHEUMATOID arthritis; NEUROTRANSMITTER uptake inhibitors

The article mentions a study which shows effectiveness of Janus kinase inhibitors (JAK) inhibitors in treatment of psoriatic arthritis (PsA). Topics discussed include that the Food and Drug Administration (FDA) first approved tofacitinib (brand name Xeljanz) to treat PsA in 2017, then the FDA approved JAK inhibitor for PsA "upadacitinib" under the brand name Rinvoq in December 2021 and mentions that these new medications provide targeted therapy to help prevent the immune system's response.